Ultimately, we used CRISPRi technology to validate the involvement of two lncRNAs, CASC19 and LINC00460, in CRC disease progression, thereby demonstrating the potential of our approach in the identification of functional lncRNAs and novel RNA drug targets. Here, CASC19 is linked to colorectal carcinoma.